Non-GLP-1 Medications: The platform also describes access to non-GLP-1 options including Contrave (bupropion-naltrexone), metformin , topiramate , and zonisamide - medications that target different mechanisms related to appetite, cravings, blood sugar regulation, and metabolic function
Retatrutide (LY3437943) is a synthetic investigational peptide that simultaneously activates three key metabolic hormone receptors: GLP-1R, GIPR, and GCGR
Reed, J
doi: 10.1016/S0893-133X(02)00306-8CrossRefGoogle Scholar Trabado, S., Al-Salameh, A., Croixmarie, V., Masson, P., Corruble, E., Fve, B., Chanson, P
Differentiating between the two requires careful observation and communication with your doctor
honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Roche Diabetes Care, Sanofi-Aventis